Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 150 of 248 entries
View as:

SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC

Phase: N/A Priority: Normal
NCT ID: NCT06457906 Org: User:
Start: 09/01/23 End: 02/28/28 Due: 02/28/29

Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC

Phase: N/A Priority: Normal
NCT ID: NCT04791176 Org: User:
Start: 04/12/21 End: 04/30/24 Due: 04/30/25

Using 4D Urinary Proteomics to Predict and Evaluate Treatment Response in Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06904677 Org: User:
Start: 05/01/25 End: 05/01/29 Due: 05/01/30

Multi-omics Analysis to Characterize the Invasive Evolution of Pulmonary Subsolid Nodules

Phase: N/A Priority: Normal
NCT ID: NCT06215885 Org: User:
Start: 01/22/24 End: 12/31/24 Due: 12/31/25

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05448885 Org: User:
Start: 09/01/21 End: 12/31/25 Due: 12/31/26

Familial Breast Cancer in China

Phase: N/A Priority: Normal
NCT ID: NCT06833216 Org: User:
Start: 02/28/25 End: 02/28/35 Due: 02/28/36

Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT

Phase: N/A Priority: Normal
NCT ID: NCT04709380 Org: User:
Start: 03/02/21 End: 02/05/25 Due: 02/05/26

Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05815290 Org: User:
Start: 03/29/23 End: 03/30/26 Due: 03/30/27

A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug As a Radiosensitizer in Patients with Advanced Breast Cancer Brain Metastasis.

Phase: N/A Priority: Normal
NCT ID: NCT06839547 Org: User:
Start: 03/01/25 End: 09/10/28 Due: 09/10/29

Translational Research on Locally Advanced Pancreatic Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03009253 Org: User:
Start: 07/31/15 End: 12/31/19 Due: 12/31/20

Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC

Phase: N/A Priority: Normal
NCT ID: NCT06202014 Org: User:
Start: 01/31/24 End: 12/31/25 Due: 12/31/26

Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06430658 Org: User:
Start: 04/01/24 End: 12/31/27 Due: 12/31/28

Reduced Dose of Pegfilgrastim as Support for Chemotherapy for Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05283616 Org: User:
Start: 05/15/17 End: 10/15/21 Due: 10/15/22

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05983107 Org: User:
Start: 07/20/23 End: 07/15/27 Due: 07/15/28

Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients

Phase: N/A Priority: Normal
NCT ID: NCT05443646 Org: User:
Start: 09/23/22 End: 06/30/25 Due: 06/30/26

Diagnostic Significance of CTCs in Patients With Thyroid Nodules (Circulating Tumor Cells)

Phase: N/A Priority: Normal
NCT ID: NCT03772496 Org: User:
Start: 07/25/18 End: 02/20/20 Due: 02/20/21

A Study of ES014 in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06543056 Org: User:
Start: 08/20/24 End: 09/30/26 Due: 09/30/27

Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor

Phase: N/A Priority: Normal
NCT ID: NCT06540937 Org: User:
Start: 07/01/20 End: 12/30/24 Due: 12/30/25

Study on the No.253 Lymph Node Metastasis Patterns in Left-Sided Colon and Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06135571 Org: User:
Start: 09/01/23 End: 09/01/26 Due: 09/01/27

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06413992 Org: User:
Start: 05/10/24 End: 06/01/27 Due: 06/01/28

First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma

Phase: N/A Priority: Normal
NCT ID: NCT05188859 Org: User:
Start: 09/01/24 End: 09/30/27 Due: 09/30/28

ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05392699 Org: User:
Start: 05/25/22 End: 01/31/27 Due: 01/31/28

Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis

Phase: N/A Priority: Normal
NCT ID: NCT06389422 Org: User:
Start: 05/01/24 End: 04/30/27 Due: 04/30/28

Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06087068 Org: User:
Start: 08/01/22 End: 12/31/26 Due: 12/31/27

Super-Hypofractionated Partial Breast Irradiation

Phase: N/A Priority: Normal
NCT ID: NCT06615466 Org: User:
Start: 04/22/22 End: 09/30/27 Due: 09/30/28